CA3203688A1 - Plasmin-resistant peptides for improved therapeutic index - Google Patents
Plasmin-resistant peptides for improved therapeutic indexInfo
- Publication number
- CA3203688A1 CA3203688A1 CA3203688A CA3203688A CA3203688A1 CA 3203688 A1 CA3203688 A1 CA 3203688A1 CA 3203688 A CA3203688 A CA 3203688A CA 3203688 A CA3203688 A CA 3203688A CA 3203688 A1 CA3203688 A1 CA 3203688A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acids
- active agent
- seq
- peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135498P | 2021-01-08 | 2021-01-08 | |
| US63/135,498 | 2021-01-08 | ||
| US202163147711P | 2021-02-09 | 2021-02-09 | |
| US63/147,711 | 2021-02-09 | ||
| US202163221874P | 2021-07-14 | 2021-07-14 | |
| US63/221,874 | 2021-07-14 | ||
| PCT/US2022/011716 WO2022150655A1 (en) | 2021-01-08 | 2022-01-07 | Plasmin-resistant peptides for improved therapeutic index |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3203688A1 true CA3203688A1 (en) | 2022-07-14 |
Family
ID=82357479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3203688A Pending CA3203688A1 (en) | 2021-01-08 | 2022-01-07 | Plasmin-resistant peptides for improved therapeutic index |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240301003A1 (https=) |
| EP (1) | EP4274596A4 (https=) |
| JP (1) | JP2024502463A (https=) |
| KR (1) | KR20230141958A (https=) |
| AU (1) | AU2022206444A1 (https=) |
| BR (1) | BR112023013640A2 (https=) |
| CA (1) | CA3203688A1 (https=) |
| IL (1) | IL304301A (https=) |
| MX (1) | MX2023008086A (https=) |
| WO (1) | WO2022150655A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11080495B2 (en) * | 2018-10-25 | 2021-08-03 | Unified Information Devices, LLC | Animal motion and temperature monitoring |
| WO2024149230A1 (zh) | 2023-01-09 | 2024-07-18 | 北京拓界生物医药科技有限公司 | 一种神经保护性psd-95多肽抑制剂及其应用 |
| EP4706670A1 (en) | 2023-04-26 | 2026-03-11 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Psd-95 domain inhibitor, and preparation method therefor and use thereof |
| CN119569824A (zh) * | 2023-09-07 | 2025-03-07 | 湖南中晟全肽生物科技股份有限公司 | 作为神经保护剂的药用化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998106B1 (en) * | 1998-12-01 | 2006-02-14 | Duke University | Radioconjugation of internalizing antibodies |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| DK2120987T3 (en) | 2007-03-02 | 2014-02-24 | Nono Inc | Treatment of stroke and other diseases without inhibiting N-type calcium channels |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| CA3018494C (en) | 2009-06-10 | 2021-12-07 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| ES2544573T3 (es) * | 2011-05-13 | 2015-09-01 | Københavns Universitet (University Of Copenhagen) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor |
| US9241970B2 (en) * | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| AU2014356912B2 (en) | 2013-12-01 | 2019-08-01 | University Of Copenhagen | Fatty acid derivatives of dimeric inhibitors of PSD-95 |
| CN106661126B (zh) | 2014-05-28 | 2021-12-10 | 诺诺公司 | TAT-NR2B9c的氯盐 |
| WO2020083905A1 (en) * | 2018-10-22 | 2020-04-30 | University Of Copenhagen | Inhibitors of pick1 and uses thereof |
-
2022
- 2022-01-07 CA CA3203688A patent/CA3203688A1/en active Pending
- 2022-01-07 KR KR1020237026532A patent/KR20230141958A/ko active Pending
- 2022-01-07 JP JP2023541501A patent/JP2024502463A/ja active Pending
- 2022-01-07 MX MX2023008086A patent/MX2023008086A/es unknown
- 2022-01-07 US US18/271,407 patent/US20240301003A1/en active Pending
- 2022-01-07 AU AU2022206444A patent/AU2022206444A1/en active Pending
- 2022-01-07 EP EP22737218.2A patent/EP4274596A4/en active Pending
- 2022-01-07 WO PCT/US2022/011716 patent/WO2022150655A1/en not_active Ceased
- 2022-01-07 BR BR112023013640A patent/BR112023013640A2/pt unknown
-
2023
- 2023-07-06 IL IL304301A patent/IL304301A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230141958A (ko) | 2023-10-10 |
| BR112023013640A2 (pt) | 2023-12-05 |
| JP2024502463A (ja) | 2024-01-19 |
| EP4274596A4 (en) | 2024-12-25 |
| IL304301A (en) | 2023-09-01 |
| US20240301003A1 (en) | 2024-09-12 |
| MX2023008086A (es) | 2023-08-01 |
| AU2022206444A1 (en) | 2023-07-20 |
| WO2022150655A1 (en) | 2022-07-14 |
| EP4274596A1 (en) | 2023-11-15 |
| AU2022206444A9 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7143374B2 (ja) | 虚血のための組み合わせ療法 | |
| US20240301003A1 (en) | Plasmin-resistant peptides for improved therapeutic index | |
| AU2010258664B2 (en) | Model systems and treatment regimes for treatment of neurological disease | |
| US10046060B2 (en) | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory | |
| US20230055441A1 (en) | Plasmin-resistant peptides for treating stroke and related conditions | |
| CN104053448B (zh) | 一种蛛网膜下腔出血及局部缺血的治疗方法 | |
| US20230139826A1 (en) | Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion | |
| US20230285504A1 (en) | Inhibition of reperfusion injury with a psd-95 inhibitor | |
| HK40096295A (zh) | 用於提高治疗指数的抗纤溶酶肽 | |
| CN116897051A (zh) | 用于提高治疗指数的抗纤溶酶肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241223 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260218 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260219 |